Test on Medical Ethics in Pediatric End-of-Life Care
Medical Ethics in Pediatric End-of-Life Care: A Guide
Test: Medical ethics
20 questions
Question 1: The experimental nucleoside replacement therapy, proven effective for TK2 mutation, was considered an ethically straightforward option for Charlie Gard.
A. Ano
B. Ne
Explanation: The study materials indicate that while limited data suggested the therapy was effective for TK2 mutation (leading to myopathy), it was unclear if it would be efficacious for Charlie Gard's RRM2B mutation, which caused an epileptic encephalomyopathy. This uncertainty meant its administration would be considered compassionate use, not an ethically straightforward option, as its benefit to Charlie was unknown, and ethical debate revolved around beneficence and nonmaleficence.
Question 2: Is it consistent with the basic ethical principle of autonomy for physicians and courts to unilaterally withdraw care over a patient's or family's objections in cases of perceived medical futility, especially when a nonmaleficent and possibly beneficent option is available?
A. Ano
B. Ne
Explanation: The study materials state that it defies the basic ethical principle of autonomy for physicians and courts to unilaterally withdraw care over a patient's or family's objections in cases of perceived medical futility, especially when a nonmaleficent and possibly beneficent option is available.
Question 3: The decision by Great Ormond Street Hospital (GOSH) to prevent Charlie Gard from receiving experimental therapy elsewhere upheld the ethical principle of patient autonomy.
A. Ano
B. Ne
Explanation: The study materials state that GOSH's denial of Charlie's opportunity to receive therapy elsewhere violated the ethical principle of patient autonomy. Allowing Charlie's parents to make medical decisions on his behalf would have demonstrated respect for their autonomy, but this was not the case.
Question 4: Great Ormond Street Hospital's (GOSH) denial of Charlie Gard's opportunity to receive experimental therapy elsewhere was considered a violation of the ethical principle of patient autonomy.
A. Ano
B. Ne
Explanation: The study materials state: "Thus, even if GOSH did not believe it was appropriate to administer the experimental therapy, it does not seem to be just of them to deny Charlie the opportunity to receive the therapy elsewhere, as this violated the ethical principle of patient autonomy."
Question 5: The experimental nucleoside replacement therapy, which was considered for Charlie Gard's RRM2B mitochondrial DNA depletion syndrome, had previously shown limited data suggesting effectiveness for another mitochondrial DNA depletion syndrome caused by a TK2 mutation.
A. Ano
B. Ne
Explanation: Limited data suggested that nucleoside replacement therapy was effective for another mitochondrial DNA depletion syndrome, a TK2 mutation, which led to improved muscle strength and head support in a 3-year-old child and significantly prolonged the lifespan of mice with this disorder. However, it was not known if it would help a patient with an RRM2B mutation.